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1. Introduction 
1.1 A Metabolic Approach to Heart Failure 
During the past half-century, the advances in the prevention, diagnosis, and management of 
cardiovascular disease (CVD) have been nothing short of spectacular. Age-adjusted CVD-related 
deaths have declined by about two-thirds in industrialized nations (1). Mortality rates associated with 
the acute coronary syndromes, valvular and congenital heart disease, uncontrolled hypertension, and 
many arrhythmias all have fallen dramatically. 
Heart failure (HF) is a notable exception to these encouraging trends. Indeed, after normal 
delivery, it is the most common cause of hospitalization. Annual hospital discharges in patients with 
a primary diagnosis of HF have risen steadily since 1975, and now exceed 1 million discharges per 
year in the United States, although they may at last be levelling off (2) (Figure 1A), or actually 
decreasing (3, 4). In Europe, hospitalizations for HF are clearly declining (5, 6). HF is primarily a 
disease of the elderly that affects about 10% of men and 8% of women over the age of 60 years, and 
its prevalence rises with age (Figure 1B) and has risen overall. In the United States, patients with a 
primary diagnosis of HF now make >3 million physician visits per year (2).  
Survival after a diagnosis of HF has improved during the past 30 years; the age-adjusted death 
rate has declined (3, 4, 7), and the mean age at death from HF has risen (5, 8). However, despite these 
modest improvements, the 5-year mortality is still approximately 50% worse than that of many 
cancers (9).  
There are many reasons why a human heart can fail (ischemic heart disease, myocarditis, 
valvular diseases, etc) (10), but the available evidence suggests that the failing heart is an engine out 
of fuel — that is, altered energetics play an important role in the mechanisms of HF (11). The heart 
consumes more energy than any other organ. It cycles about 6 kg of ATP every day — 20 to 30 times 
its own weight. Each day, it beats about 100,000 times and pumps approximately 10 tons of blood 
through the body. To acquire the energy that is necessary to carry out its function, the heart converts 
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chemical energy stored in fatty acids and glucose into the mechanical energy of the actin–myosin 
interaction of myofibrils. Failure to produce an adequate amount of energy causes mechanical failure 
of the heart (12). The concept that the failing heart is an energy-starved engine that has run out of 
fuel is decades old. It was proposed in 1939 by Herrmann and Decherd (13), who, in their article 
entitled “The Chemical Nature of Heart Failure,” described a significantly reduced creatine content 
in failing myocardium. It is today well known that, in the end-stages of HF, the myocardium has low 
ATP content due to a decreased ability to generate ATP by oxidative metabolism, and thus is unable 
to effectively transfer the chemical energy from the metabolism of carbon fuels to contractile work 
(14, 15). The consequences of metabolic dysfunction in HF are poorly understood, but there is 
growing evidence to support the concept that the alterations in substrate metabolism seen in HF 
contribute to contractile dysfunction and to the progression of left ventricular (LV) remodelling that 
are characteristic of the HF state. Current medical therapies for HF are aimed at suppressing 
neurohormonal activation (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor 
antagonists, ß-adrenergic receptor antagonists, and aldosterone receptor antagonists), and treating 
fluid volume overload and hemodynamic symptoms (diuretics, digoxin, inotropic agents) (16-21). 
These pharmacotherapies for HF can improve clinical symptoms and slow the progression of 
contractile dysfunction and expansion of LV chamber volume; nevertheless, there is still progression, 
and the prognosis for even the optimally treated patient remains poor (2). Moreover, there is recent 
evidence that intense suppression of the neurohormonal systems does not provide further benefit 
compared with more modest therapy (22, 23). Thus, there is a need for novel therapies for HF, 
independent of the neurohormonal axis, that can improve cardiac performance and prevent or reverse 
the progression of LV dysfunction and remodelling. 
 
1.2 Overview of Normal Myocardial Substrate Metabolism 
The heart has a very high energy demand and essentially no energy reserves. So, it must continually 
generate ATP at a high rate to sustain contractile function, basal metabolic processes, and ionic 
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homeostasis (24). In the normal adult heart, almost all (>95%) of ATP production is derived from 
mitochondrial oxidative phosphorylation, with the remainder being derived from glycolysis and GTP 
formation in the tricarboxylic acid (TCA) cycle. The heart has a relatively low ATP content (5 µmol/g 
wet wt) and high rate of ATP hydrolysis (» 30 µmol × g wet wt-1 × min-1 at rest); thus, under normal 
conditions, there is complete turnover of the myocardial ATP pool approximately every 10 s (25-27). 
To sustain sufficient ATP generation, the heart acts as an “omnivore” and can use a variety of 
different carbon substrates as energy sources if available (28, 29) (Figure 2). However, the adult 
heart normally obtains 50– 70% of its ATP from fatty acid b-oxidation (25, 27, 30). The b-oxidation 
of fatty acids is under complex control and is dependent on a number of factors, including 1) fatty 
acid supply to the heart; 2) the presence of competing energy substrates (glucose, lactate, ketones, 
amino acids); 3) energy demand of the heart; 4) oxygen supply to the heart; 5) allosteric control of 
fatty acid uptake, esterification, and mitochondrial transport; and 6) the control of mitochondrial 
function, including direct control of fatty acid b-oxidation, TCA cycle activity, and electron transport 
chain activity (28, 31, 32). The transcriptional control of enzymes involved in fatty acid metabolism 
and mitochondrial biogenesis are also important determinants of fatty acid b-oxidation rates (33). Of 
importance, is that the normal heart has a substantial amount of “metabolic flexibility” that allows it 
to switch back and forth between fatty acids and carbohydrates oxidation, depending on the workload 
of the heart, the energy substrate supply to the heart, and the hormonal and nutritional state. For 
instance, an increase in fatty acid oxidation rates in the heart, is accompanied by a dramatic decrease 
in the oxidation of pyruvate originating from glucose (glucose oxidation), and vice versa (24). This 
metabolic flexibility allows the heart to produce the necessary amount of ATP needed by the heart to 
sustain cardiac contractility under a wide variety of conditions. 
In the fasting state, ketones are taken up by the human heart, along with glucose, lactate, 
pyruvate, glycerol, and fatty acids, with the highest avidity per unit mass among body tissues and 
with a fractional extraction (~ 40%) comparable to that of pyruvate and far higher than that of glucose 
(~ 2%) or fatty acids (15–20%) (34). By combining mass uptake (~ 10 mmol/min) with the heat of 
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combustion, it can be calculated that in the overnight fasted state the ketone body ß-hydroxybutyrate 
contributes 15% of resting cardiac energy expenditure compared with 45% of fatty acids and 8% of 
glucose/lactate/pyruvate.  
 
1.3 Derangement of Energy Metabolism in Heart Failure 
Heart failure has a complex pathophysiology, which is attributed to differences in aetiology, severity, 
disease duration, and comorbidities such as diabetes and obesity. Furthermore, these factors 
themselves can greatly affect myocardial energy metabolism (24).  
Regardless of the type of heart failure, cardiac energy metabolism can be compromised 
(Figure 3). This is evidenced by in vivo measurements of ATP and phosphocreatine (PCr) content 
(using 31P-magnetic resonance spectroscopy) in the human failing heart, that can be approximately 
30-40% lower than in the normal heart (35, 36). Cardiac PCr/ATP ratios are decreased in HF and 
correlate with New York Heart Association (NYHA) functional class, predicting adverse outcomes 
of these patients (35, 36). This energy deficit in the failing heart is partly attributable to defects in 
mitochondrial function and electron transport chain activity (37, 38), but also to alterations in energy 
substrate use by the heart that can decrease cardiac efficiency (39, 40). 
The changes in energy substrate preferences that occur in HF are controversial and not 
completely understood. It is generally assumed that the failing heart switches from fatty acid to 
glucose metabolism in the failing heart (12, 41, 42). Studies of substrate utilization in HF have yielded 
conflicting results, but most experimental data indicate that fatty acid utilization, which is unchanged 
or slightly increased in early HF (43, 44), is substantially decreased in advanced heart failure (45). 
However, it is probably more accurate to suggest that the heart switches from mitochondrial oxidative 
metabolism towards glycolysis as a source of ATP production (39, 46). A decrease in fatty acid 
oxidation in HF likely occurs both due a decrease in overall mitochondrial function and oxidative 
capacity, as well as a decrease in the transcription of a number of enzymes involved in fatty acid 
oxidation (12, 37, 41). However, mitochondrial glucose oxidation can also decrease dramatically in 
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the failing heart, that occurs due both to a decrease in overall mitochondrial oxidative capacity, and 
a decrease in the activity of the key rate-limiting enzyme of glucose oxidation, pyruvate 
dehydrogenase (39, 46). This decrease in glucose oxidation coupled to an increase in glycolytic rates, 
results in a mismatch between glycolysis and glucose oxidation. This mismatch between glycolysis 
and glucose oxidation results in an increase in lactate and proton production by the heart, similar to 
what is seen in ischemic heart disease (39), that in turn can lead to intracellular Na+ and Ca2+ overload, 
and finally to an impaired cardiac power and performance (47-49).  
Clinical studies demonstrate that at a late stage HF results in an increase in plasma ketone 
body concentration that appears to be secondary to elevated fatty acid levels (50-52). Ketones, and in 
particular ß-hydroxybutyrate, demonstrated in experimental observations to have a highly beneficial 
energetic profile (53).  The energetics of mitochondrial ß-hydroxybutyrate oxidation compares 
favourably with the oxidation of pyruvate; in fact, when ß-hydroxybutyrate is added to the perfusion 
medium of working rat hearts, the heat of combustion per unit of carbon has been calculated to be 
31% increased and the oxygen cost of this energy output to be 27% decreased (54). This advantage 
is granted by a more efficient oxidation of the mitochondrial coenzyme Q couple and an increase in 
the free energy of cytosolic ATP hydrolysis. As a consequence, in the isolated working heart ß-
hydroxybutyrate increases external cardiac work at the same time as it reduces oxygen consumption, 
thereby improving cardiac efficiency by 24% 
 
1.4 Ketone Body Metabolism 
Ketone bodies, that are β-hydroxybutyrate, acetoacetate and acetone (in low abundance), are 
produced in the liver and used in peripheral tissues as an energy source when glucose is not readily 
available because of either a limited exogenous supply or impaired insulin signalling or when fatty 
acids are in surplus, which occurs in marked activation of lipolysis (55). The heart extracts and 
oxidizes ketone bodies in a concentration-dependent manner (56-59). Plasma ketone bodies are 
formed from fatty acids in the liver, and the arterial plasma concentration is normally very low, thus 
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they are normally a minor substrate for the myocardium. During starvation and poorly controlled 
diabetes, plasma ketone body concentrations are elevated secondary to low insulin and high fatty 
acids, and they become a major substrate for the myocardium (60, 61). On entering the cell, they 
rapidly form acetyl-CoA via a series of reactions catalysed by ß-hydroxybutyrate dehydrogenase, 
succinyl-CoA:3-oxoacid-CoA transferase (SCOT), and mitochondrial acetyl-CoA acetyltransferase 
(62) and enter in the TCA cycle (Figure 4). All enzymes are present in the heart, and the reactions 
are driven primarily by substrate availability, except for the SCOT reaction, which is a succinyl CoA–
dependent process.  
As with fatty acids, the uptake and oxidation of glucose and lactate are inhibited by elevated 
plasma ketone bodies (30, 63), with the inhibitory effect presumably mediated through product 
inhibition on pyruvate dehydrogenase. Oxidation of ketone bodies inhibits also myocardial fatty acid 
oxidation (56-58, 63, 64).  
As a function of oxygen consumption, ketone bodies are the most efficient substrate for ATP 
production and therefore could be a particularly useful fuel source under conditions in which oxygen 
delivery to tissues is reduced, such as in advanced HF (54, 65). Furthermore, manifest and latent 
deficiencies of ketone bodies utilization are associated with cardiomyopathy. The OXCT1 gene 
encodes a mitochondrial matrix enzyme that is essential for ketone body oxidation, SCOT (65, 66). 
Some individuals with recessive mutations of OXCT1 present with dilated cardiomyopathy (67). In 
addition, ketogenic diets cause biochemical disturbances and cardiac dysfunction in certain 
vulnerable patients, possibly due to latent defects in ketone body metabolism (68). These findings 
support the hypothesis that ketone body can play a role in the HF myocardial metabolism. 
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2. Rationale and Aim of the Study 
Despite advances in the treatment of HF, our understanding of the energy metabolic mechanisms 
limiting cardiac pump function remains incomplete. It is increasingly recognized that metabolic 
remodelling is integral to HF development and progression (12, 42) and that the overall reduction in 
the myocardial oxidative capacity is purported to be the root cause of energy deficiency in the failing 
heart.   
An elevation in serum KBs levels has been observed by several studies in patients with HF 
(51, 69). Interestingly, a new glucose-lowering agent, the sodium–glucose cotransporter 2 (SGLT2) 
inhibitor empaglifozin, was demonstrated to increase ketogenesis in type 2 diabetes (T2D) (70). In 
the EMPA-REG OUTCOME trial, that tested empagliflozin against placebo in 7,020 patients with 
T2D who were at increased cardiovascular risk a striking relative risk reduction in cardiovascular 
outcomes was found (71). These beneficial effects of empagliflozin has been proposed to be due an 
increase in ketone use by the heart, and it has been proposed that ketones are a “superfuel” for the 
heart that can increase cardiac efficiency and, in turn, cardiovascular protection beyond the classical 
mechanisms described for glucose lowering agents (i.e. improvement in glycaemic control, decrease 
in body weight, reductions in blood pressure and uric acid level) (72). Moreover, experimental 
observations showed that KBs improve work efficiency at the mitochondrial level (54), suppress 
oxidative stress by inhibiting histone deacetylases (73), upregulate mitochondrial biogenesis and, by 
stabilizing cell membrane potential, exhibit antiarrhythmic potential (55).  
Finally, recent proteomics and metabolomics studies demonstrated strong and concordant 
evidence of increased ketone bodies oxidation in HF providing new insights into the reliance of the 
failing heart on ketone bodies for energy supply (Figure 5). In particular, Aubert et al. (74)  examined 
longitudinal changes in cardiac energy metabolism during the development of HF murine models of 
compensated hypertrophy and HF. Using a proteomic approach, this group identified significant 
downregulation of proteins involved in fatty acid utilization in both compensated hypertrophy and 
HF hearts with a concurrent 2- to 3-fold increase in b-hydroxybutyrate dehydrogenase (BDH1), the 
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enzyme that catalyzes the initial step in the ketone oxidation pathway. Moreover, the authors found 
increases in hydroxybutyrylcarnitine and acetylcarnitine in the HF group, a known metabolic 
signature of ketone metabolism. Bedi et al. (75) described an independent study of end-stage human 
HF in which metabolomics analysis showed increased ketogenic b-hydroxybutyrate-CoA and 
evidence for enhanced myocardial utilization of b-hydroxybutyrate. These changes were 
accompanied by an upregulation of BDH1, BHD2 (cytosolic isoform), and succinyl-CoA:3-oxoacid-
CoA transferase (SCOT), key enzymes in the ketone oxidation pathway.  
Data described in literature provide just clues on HF metabolism in humans (animal models, 
end-stage HF, small populations). The main aim of our study was to identify and quantify myocardial 
substrates utilization in mild to moderate human HF. We hypothesized to that failing hearts would 
display signs of reduced fatty acid uptake in favor of ketone bodies. 
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3. Methods 
3.1 Patients Selection  
Patients who satisfying criteria of HF with reduced ejection fraction (HFrEF) according to the current 
guidelines by European Society of Cardiology (76) and an indication to implant a cardiac device 
(cardiac resynchronization therapy/implantable cardiac defibrillator/single or dual-chamber 
pacemaker) were enrolled. In particular, chronic stable patients, who presented with signs or 
symptoms of HF (dyspnoea, fatigue, and exercise intolerance) consistent with a New York Heart 
Association (NYHA) functional class II to III and reduced left ventricle ejection fraction (<40%) 
were considered suitable for screening.   
Exclusion criteria included: severe obesity (body mass index>40); acute heart illness (i.e. 
myocarditis, acute coronary syndrome, atrial permanent arrhythmias); infiltrative or hypertrophic 
cardiomyopathy; cancer in the active phase; hepatitis B or C; human immunodeficiency virus; severe 
renal disease (glomerular filtration rate <15 ml/m).    
All patients received standard medical therapy per discretion of the attending cardiologists 
and must provide informed consent. The control group was represented by non-HF patients scheduled 
for single or dual chambers pacemaker implantation. The study was approved by the local ethical 
committee and all patients signed written informed consent. 
 
3.2 Study Protocol  
Study population and controls were enrolled in the investigational Centre (Institute for Clinical and 
Experimental Medicine, Prague, Czech Republic). Patients with HFrEF and clinical indication to 
implant a cardiac device were screened to be part of the study population, while patients without HF 
and scheduled to implant a cardiac device were screened to be part of the control cohort.  
All patients underwent to a complete cardiac evaluation, including clinical history, the Kansas City 
Cardiomyopathy Questionnaire (KCCQ), physical examination, and echocardiogram (Vivid7, 
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General Electric Healthcare, Wauwatosa, Wisconsin). Left ventricular (LV) function and dimensions 
were measured according to contemporary recommendations (77). Mitral and tricuspid regurgitation 
was assessed semi-quantitatively and expressed in 4 grades (absent/mild, moderate, moderate to 
severe and severe). Right ventricular (RV) systolic pressure was estimated from the tricuspid 
regurgitation velocity and right atrial pressure estimate, based on inferior vena cava (IVC) diameter. 
RV function was quantified in an apical 4-chamber view by using tricuspid annular systolic excursion 
(M-mode TAPSE). Glomerular filtration rate was estimated using the Modification of Diet in the 
Renal Disease equation (78). Plasma sodium, albumin, glucose and creatinine were measured by 
using an automated Abbott Architect ci1600 analyzer. The B-type natriuretic peptide (BNP) 
concentrations were measured by using microparticle immunoassay (Architect BNP, Abbott 
Laboratories, Chicago, Illinois; long-term analytical CV 4.5%). 
 
3.3 Investigation Procedure and Substrates Analysis 
All investigations were done after at least 6-hour or overnight fast.  In every patient enrolled in the 
study we collected three blood samples within few minutes of each other. The arterial and venous 
samples were collected by the fluoroscopy-guided axillary vein puncture technique (79), while the 
coronary sinus (CS) sample was harvested by a dedicated sheet introduced via axillary vein approach 
in the CS under fluoroscopy guidance. To allow the correct sampling of all CS branches the sheet 
was placed no deeper than 1-1.5 cm into the CS body. All enrolled participants were under mild 
sedation during the procedure. Blood samples were collected after at least 10 minutes from the last 
administration of sedative drugs and without any on-going infusion to avoid sample dilution. No 
antiarrhythmic drugs or isoproterenol were administered before sampling.  
All samples were immediately placed on ice, and within 20 minutes, they were centrifugally 
separated at a centrifugal force of 800 × g at 4 °C. The plasma was collected, distributed into aliquots, 
and frozen at –80 °C. β-hydroxybutyrate concentration was analyzed instead of total ketones because 
it is the most abundant in the bloodstream (80), accounts for the larger part of the circulating ketone 
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bodies during fasting (81) and showed a significant role in cellular signaling (82). β-hydroxybutyrate, 
fatty acids and glucose concentrations were measured with use of commercially available enzymatic 
assays coupled to chromogenic substrates (Wako Chemicals USA, Inc.; Richmond, VA). Arterial and 
CS oximetric measurements (A-VOX Systems, Inc.; San Antonio, Texas) were used to calculate the 
myocardial arteriovenous difference in partial oxygen pressure. The fractional extraction (FE) of each 
substrate was computed according to the formula: FE = [(SA – SCS)/SA] x 100, where SA and SCS 
are respectively the substrates concentration in the axillary artery and in the coronary sinus. Net 
myocardial exchange (uptake or release) of substrates was computed as: SA – SCS.  
 
3.4 Statistical Analysis 
Data are presented as means ± standard deviation using conventional methods except for variables 
without normal distribution where median and interquartile range are shown. Variables not normally 
distributed had been log-transformed before the analysis. Skewness was tested using the Shapiro-
Wilk normality test. Pearson coefficient was calculated to express correlation. Statistical 
significances between groups were performed using Students unpaired t-test or Mann-Whitney U-
test. The level of statistical significance was set at a 2-sided p-value <0.05.  
All analyses were performed using JMP 9.0 statistical software (SAS Institute, Inc., Cary, 
North Carolina). 
 
 
 
 
 
 
 13 
4. Results 
4.1 Clinical Characteristics 
The mean age of patients with HF (n=16) was 68 ± 8 years, 69% were male, 44% had ischemic heart 
disease and 56% had diabetes. The main etiology of HF was idiopathic (75%) and the mean duration 
of the disease was 18 (6-44) months. Approximately 75% and 80% of patients were treated with 
mineralocorticoid antagonist (MRA) and angiotensin converting enzhyme inhibitors 
(ACEi)/angiotensin receptor blockers (ARB), respectively, 69% with beta-blockers (BB) and more 
than 80% were taking loop diuretics (Table 1). Mean LVEF was 28.2 ± 4.9% and mean QRS duration 
was 165 ± 19 msec (Table 2).  
Among controls (n=15), 45% had diabetes and 27% ischemic heart disease, and all of them had 
hypertension. Their mean age was 77 ± 9 years, 36% males (Table 1); mean LVEF was 57.1 ± 3.7% 
and mean QRS duration was 118 ± 24 msec.  
Blood biochemistry profile showed no relevant differences between groups except, as 
expected, for a higher BNP plasma concentration in HF patients compared to controls (279 [217-932] 
mmol/L vs 74 [40-150], p=0.008) (Table 2).  
 
4.2 Procedural Characteristics 
In the HF group 13 patients (81%) received a cardiac resynchronization therapy (CRT) defibrillator 
and 3 (19%) a CRT pacemaker; among these, 50% were upgrades from a single or dual-chamber 
pacemaker or defibrillator. The mean total procedural time was 90 ± 25 min. All controls were 
implanted with a dual-chamber pacemaker with a mean total procedural time of 64 ± 24 min (Table 
3). 
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All patients received intraprocedural sedation, without any significative difference between 
groups. No differences in fasting time before the procedure were noted (HF 16 ± 6 hours vs controls 
16 ± 5 hours, p=0.97) (Table 3). 
Two patients, one in the HF group and one in the control group had pericardial effusion during 
the procedure after CS cannulation. In the HF patient the effusion was complicated by cardiac 
tamponade that needed an urgent pericardiocentesis. Both patients completely recovered after few 
days of hospitalization and no chronic sequalae were registered.         
 
4.3 Myocardial Metabolism and Correlates  
We analyzed both the net myocardial exchange (arterio-venous difference) and fractional myocardial 
extraction of energetic substrates, to investigate the craving of the heart for specific substances, and 
the difference in concentration of these substrates between patients with and without HF (Table 4). 
Substrates concentrations and partial pressure of oxygen were similar in HF and non-HF 
patient both in the arterial and in the CS samples (Table 4 and Figure 6). Both net myocardial 
substrates exchange and fractional extraction showed a significant reduction in the mean myocardial 
fatty acids uptake in HF patients compared to controls (net myocardial substrates exchange: HF 0.07 
± 0.23 mmol/L vs non-HF 0.25 ± 0.16 mmol/L, p=0.03; fractional myocardial extraction: HF 4 ± 
44% vs non-HF 31 ± 19%, p=0.05). Opposite, β-hydroxybutyrate, lactate, partial pressure of oxygen, 
triacyclglycerols and glucose extractions were relatively unchanged between groups (Table 4 and 
Figure 7). When HF metabolism was tested for differences in diabetic and non-diabetic patients, no 
difference in net and fractional myocardial substrates extraction was found (Figure 8). 
In the linear regression analysis, larger end-diastolic (p<0.001) and end-systolic (p=0.001) LV 
diameters, higher aldosterone (p=0.02) and renin (p=0.05) plasma concentrations and increased right 
ventricular systolic pressure (p=0.05) and LV mass (p=0.04) were inversely correlated with the net 
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fatty acids myocardial exchange. In contrast, left ventricular ejection fraction was directly correlated 
(p=0.01) (Table 6; Figure 9 and Figure 10).  
The only variable statistically, but marginally, associated with the net β-hydroxybutyrate 
myocardial exchange was HF duration (Table 5 and Figure 11). Interestingly, β-hydroxybutyrate 
plasma concentration was associated neither with HF duration (Figure 11) nor with triacilgliceroles 
concentration, both in HF and in controls (Figure 12).  
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5. Discussion 
The main finding of our study is that there was no difference in the net and fractional extraction of β-
hydroxybutyrate in mild to moderate HFrEF compared to patients who had structurally normal hearts. 
Interestingly, the net cardiac extraction of β-hydroxybutyrate was directly associated to HF duration. 
We also demonstrated a reduced myocardial fatty acids uptake in HF patients and its negative 
association with neurohormonal and echocardiographic HF hallmarks.  
Previous human and experimental studies showed an increased reliance of the failing heart on 
ketone bodies for energy supply in severe or end-stage HF (51, 74, 75). This metabolic change was 
mirrored by the upregulation of the key enzymes in the ketone oxidation pathway such as BDH1, 
BHD2 (cytosolic isoform), and SCOT (75). Whether the switch in myocardial substrate oxidation 
away from fatty acids toward ketones in advanced HF is a positive compensatory adaptation or a 
pathological maladaptation is a matter of considerable debate, but it has been proposed that this switch 
is energetic beneficial and can maintain cardiac energy supply under situation of limited energy 
production (55). An interesting insight in this field came from the EMPA-REG OUTCOME trial (71) 
where the striking reduction of cardiovascular outcomes and mortality were partly adduced to an 
empaglifozin-mediated increase in plasma concentration of ketone bodies (72, 83).  
In our study we found that plasma concentration of β-hydroxybutyrate in the artery and CS 
and its net and fractional myocardial extraction were unchanged compared to controls. These 
differences with previous studies could be explained in first instance by different population 
characteristics. Aubert et al. (74) evidenced the increase of key enzymes in the ketone oxidation 
pathway in a murine model of compensated hypertrophy and HF. Lommi et al. demonstrated an 
increase in ketone bodies plasma concentrations in 45 highly symptomatic patients with chronic 
moderate to severe HF (29 patients in NYHA class III or IV) not on betablockers therapy. Recently, 
Bedi et al. (75) showed increased ketogenic β-hydroxybutyrate-CoA and evidence for enhanced 
myocardial utilization of β-hydroxybutyrate in end-stage human HF. Opposite, we enrolled patients 
with mild to moderate HF (NYHA class II-III), in a stable phase and well medically treated. 
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We also found a direct correlation between β-hydroxybutyrate myocardial extraction and HF 
duration. This finding is in according to previous experimental observations in dogs where changes 
in substrate use were a late-stage phenomenon and a consistent myocardial metabolic switch occurred 
only in more severe or decompensated HF (43). Interestingly, β-hydroxybutyrate plasma 
concentration was associated neither with HF duration nor with fatty acids concentration, both in HF 
and in controls. While the uncoupling between β-hydroxybutyrate plasma concentration and HF 
duration may be due to the observation of an early phase of metabolic remodeling, and so to the scarce 
rely of the heart on ketone bodies for its energetic supply, the poor relation between ketones and fatty 
acids concentration is probably multifactorial. One possible cause may be the high level of 
neurohormonal blockade in our HF patients that, reducing the sympathetic overdrive, can lead to a 
low rate of lipolysis (50). Another possible explanation may be that in our population insulin was still 
effective in the heart metabolism control (low level of tissues insulin-resistance), and therefore in 
suppressing ketogenesis (55).  
We studied both diabetics and non-diabetics patients. It is well-known that diabetic hearts 
cannot use glucose fully due to shortage of insulin effects and may therefore be forced to switch to 
almost exclusive use of fatty acids for energy sources (84). This metabolic signature may change the 
utilization of energy substrates between diabetic and non-diabetic failing heart. In our study we didn’t 
find any difference in substrate utilization between patients in HF with and without diabetes. This 
was probably due to the well-controlled glycemic status of all enrolled diabetic patients.  
As outlined in the Introduction, studies in animals provide a consistent view that failing heart 
have reduced fatty acid uptake whereas the few studies in humans are largely conflicting (24). 
Paolisso et al. (85) measured the net extraction of fatty acids by the myocardium using simultaneous 
arterial and CS sampling in patients with mild to moderate HF (NYHA class II-III) and in age-
matched healthy individuals. HF patients had elevated plasma norepinephrine and insulin as well as 
a 50% increase in fatty acids concentrations. Fatty acids uptake and the estimated fatty acid β-
oxidation rates were » 40% higher in HF patients than in controls, despite no difference in coronary 
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blood flow or the rate of cardiac energy expenditure. More recently, direct measurements of fatty 
acids oxidation were made in patients with dilated cardiomyopathy using an infusion of [3H]-oleate 
tracer and arterial and CS sampling to assess oxidation to 3H2O (86). Arterial fatty acids concentration 
was not different between groups. Compared with controls, HF patients have reduced uptake and 
oxidation of fatty acids both in absolute terms and when normalized to myocardial oxygen 
consumption.  
We showed a slight reduction in the fatty acids net and fractional myocardial extraction in 
patients with HF compared to controls. Moreover, we demonstrated an inverse association between 
fatty acids myocardial uptake and neurohormonal and echocardiographic HF hallmarks. These 
findings are consistent with an initial down-regulation of β-oxidation in our HF population, with a 
reduction in myocardial fatty acids uptake concordant with the worsening of HF. This suggests that 
the basic pattern of substrate utilization may function on a continuum, with only slight modifications 
in the early stages (i.e. mild down-regulation of β-oxidation but still no evidence of increased ketones 
or glucose utilization) and a stronger compensatory switch in end-stage HF as an attempt to “rescue” 
the myocardium when the function has become severely compromised (28, 43, 51, 75). 
In light of our results we believe that the degree of cardiac metabolic derangement could give 
insight into the severity of HF, and that a reduced extraction of fatty acids after an overnight fast may 
be considered as a warning of incipient problems with the maintenance of the body’s energy stores. 
Whether these metabolic changes may have a role in the prognosis, such as neurohormonal activation 
or BNP plasma concentration, deserves attention in future studies. 
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6. Study Limitations 
This study presents some limitations that should be acknowledged. Highly optimized and managed 
treatment of our HF cohort may have influenced by some degree cardiac metabolic changes, that 
could be mitigated (87). We observed an excess of dilatative cardiomyopathy (probably due to a 
referral bias) in our HF group, so the extension to other HF categories of our results should be 
cautious. The number of patients enrolled in each group was low, so the respective differences 
between the groups need to be confirmed in larger cohorts. A potential confounding variable between 
the groups was the difference in age distribution (proportionately patients in HF group were younger). 
In fact, clinical observations showed an altered myocardial metabolism and substrate flexibility (88) 
with ageing and a consequent decreased capacity to oxidize fatty acids (89). All patients underwent 
to mild sedation with low doses of midazolam and fentanyl during implanting procedure. Although 
fentanyl might alter circulating metabolites at high doses (90) (no clear data on midazolam), no data 
are available for low doses. Anyway, the mean dose of anesthetic drugs in our study was very low 
and similar between groups (so if any effects was present, it should be equally distributed in the 
groups). We enrolled as controls patients who had structurally normal hearts and with the indication 
to implant a cardiac pacemaker for sick sinus syndrome or atrio-ventricular block (AVB). Among 
these, approximately 19% had a high-degree AVB. We don’t know if this condition could have 
induced any degree of cardiac metabolic changes in substrates uptake and utilization, in turn 
impacting on our final results. Finally, in our study we didn’t measure blood flow as well as substrate 
oxidation, that could provide a better understanding of the heart ability in substrates extraction and 
utilization.  
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7. Conclusions 
In patients with HF and systolic disfunction the cardiac extraction of β-hydroxybutyrate was similar 
to patients who had structurally normal hearts. The net cardiac extraction of β-hydroxybutyrate was 
slightly and directly associated to HF duration. A reduced myocardial fatty acids uptake in HF 
patients, consistent with a downregulation of β-oxidation, and its association to neurohormonal and 
imaging hallmarks of HF was also showed.  
Further studies are needed to fully assess myocardial metabolic phenotype changes over the 
progression from mild to advanced and end-stage HF and if these metabolic changes may have a role 
in the prognosis and in future therapeutic approaches.  
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10. Tables 
 
 
Table 1. Clinical characteristics of HF patients and controls 
 
List of abbreviations: HF, heart failure; NA, not applicable; NYHA, New York Heart Association; COPD, Chronic obstructive 
pulmonary disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; KCCQ, Kansas City 
Cardiomyopathy Questionnaire.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 HF patients (n=16) Controls (n=15) p-value 
Age – years 68 ± 8 77 ± 9 0.02 
Male – no. (%) 11 (69) 4 (36) 0.09 
Body surface area – m2 2.0 ± 0.2 1.9 ± 0.3 0.18 
Body mass index – Kg/m2 28.2 ± 4.4 28.2 ± 4.2 0.97 
NYHA class 
NYHA class II – no. (%) 
NYHA class III-IV – no. (%) 
 
7 (44) 
9 (56) 
NA NA 
KCCQ sum score 43 ± 12 NA NA 
Heart failure duration - months 18 (6-44) NA NA 
Heart failure etiology  
Ischemic – no. (%) 
Idiopathic – no. (%) 
Others – no. (%) 
 
2 (13) 
12 (75) 
2 (12) 
NA NA 
Systolic blood pressure – mmHg 136 ± 25 150 ± 27 0.18 
Diastolic blood pressure - mmHg 72 ± 9 69 ± 8 0.31 
Hypertension – no. (%) 10 (63) 15 (100) 0.01 
Ischemic heart disease – no. (%) 7 (44) 3 (27) 0.38 
Diabetes mellitus – no. (%) 9 (56) 5 (45) 0.58 
Dyslipidemia – no. (%) 9 (56) 8 (73) 0.38 
Smoking habit – no. (%) 10 (63) 2 (18) 0.02 
COPD/asthma – no. (%) 4 (25) 0 0.03 
Furosemide use – no. (%) 13 (81) 2 (18) <0.001 
Mineralocorticoid antagonist use – no. (%) 12 (75) 2 (18) 0.002 
ACEi or ARB use – no. (%) 13 (81) 15 (100) 0.06 
Sacubitril-Valsartan use – no (%) 2 (13) 0 0.14 
Beta blocker use – no. (%) 11 (69) 2 (18) 0.01 
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Table 2. Biochemical, electrocardiographic and echocardiographic characteristic of the study 
population and controls 
 HF patients (n=16) Controls (n=15) p-value 
Blood biochemistry 
Sodium – mmol/L 139.2 ± 2.0 137.8 ± 3.1 0.20 
Potassium – mmol/L 4.2 ± 0.3 4.2 ± 0.3 0.47 
Chloride – mmol/L 106.1 ± 5.1 106.5 ± 3.2 0.94 
Total proteins – g/L 62.9 ± 5.5 62.8 ± 2.9 0.93 
Albumin – g/L 37.1 ± 2.0 37.6 ± 1.1 0.49 
C-reactive protein – mg/L 2.1 (1.0; 10.0) 1.5 (0.7; 2.4) 0.09 
GFR-MDRD – (mL/min/1.73 m2) 71.2 ± 25.3 76.4 ± 27.7 0.63 
Urea – mmol/L 7.7 (5.7; 9.4) 5.9 (4.9; 8.5) 0.20 
Total Cholesterol – mmol/L 4.7 ± 1.3 3.9 ± 0.8 0.08 
Triacylglycerol – mmol/L 1.6 ± 1.4 1.0 ± 0.3 0.11 
Glucose – mmol/L 6.6 ± 2.4 5.7 ± 1.3 0.21 
Glycated hemoglobin – mmol/mol 46.3 ± 11.2 44.9 ± 2.4 0.71 
Brain natriuretic peptide – mmol/L 379 (217; 932) 74 (40; 150) 0.008 
Aldosterone – pmol/L 209 (123; 385) 180 (73; 273) 0.25 
Renin – ng/L 15 (6; 89) 57 (20; 88) 0.33 
Hemoglobin – g/L 124 (116; 131) 125 (120; 130) 0.83 
 
Electrocardiography 
Heart rate – bpm 69 ± 13 59 ± 12 0.05 
Left bundle branch block – no. (%) 16 (100) 1 (7) <0.001 
Right bundle branch block – no. (%) 0 4 (36) 0.004 
QRS duration - msec 165 ± 19 118 ± 24 <0.001 
 
Echocardiography 
Left atrium volume index – ml/m2 50.2 ± 15.9 44.7 ± 10.2 0.30 
Left ventricular end diastolic volume - ml 208.3 ± 96.5 105.3 ± 30.7 <0.001 
Left ventricular end systolic volume - ml 154.9 ± 82.5 42.2 ± 15.4 <0.001 
Left ventricular ejection fraction - % 28.2 ± 4.9 57.1 ± 3.7 <0.001 
TAPSE - mm 19.3 ± 4.4 21.2 ± 3.2 0.29 
Left ventricular mass index – gr/m2  138.1 ± 28.9 84.4 ± 23.3 <0.001 
E/e’ ratio 13.9 ± 8.2 9.3 ± 3.5 0.08 
Mitral regurgitation 
Grade 1-2 – no. (%) 
Grade 3-4 – no. (%) 
 
10 (62) 
6 (38) 
 
15 (100) 
0 
0.02 
Tricuspid regurgitation 
Grade 1-2 – no. (%) 
Grade 3-4 – no. (%) 
 
15 (93) 
1 (7) 
 
13 (91) 
2 (9) 
0.05 
Right ventricular systolic pressure - mmHg 36.0 ± 13.8 22.4 ± 6.4 0.006 
Inferior vena cava diameter - mm 19 ± 6 17 ± 4 0.36 
List of abbreviations: TAPSE, tricuspid annular plane systolic excursion; HF, heart failure. 
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Table 3. Intraprocedural data for HF patients and controls 
 HF patients (n=16) Controls (n=15) p-value 
Type of device 
Dual-chamber pacemaker – no (%) 
CRT-D – no. (%) 
CRT-P – no. (%) 
 
0 
13 (81) 
3 (19) 
 
15 (100) 
0 
0 
<0.001 
Type of procedure 
First implant – no (%) 
Upgrade – no (%) 
 
8 (50) 
8 (50) 
 
15 (100) 
0 
0.005 
Fasting before procedure - hours 16 ± 6 16 ± 5 0.97 
Intraprocedural sedation – no. % 16 (100) 15 (100) 1.00 
Midazolam average dose - mg 2.6 ± 1.5 2.2 ± 1.0 0.41 
Fentanyl average dose – mcg 262 ± 96 236 ± 81 0.45 
Oxygen saturation - % 97.2 ± 1.9 98.5 ± 1.1 0.06 
Oxygen administration# – L/m 3.3 ± 0.8 3.5 ± 0.7 0.62 
Total procedural time - min 90 ± 25 64 ± 24 0.01 
Total x-ray time - min 12.5 ± 9.8 5.3 ± 2.7 0.01 
Complications – no. (%) 1 (7) 1 (8) 0.79 
# oxygen administered by nasal cannula.  
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Table 4. Heart metabolism in HF patients and controls 
 HF patients (n=16) Controls (n=15) p-value 
Arterial blood  
3β-hydroxybutyrate – mmol/L 0.40 ± 0.20 0.52 ± 0.32 0.31 
Free fatty acids – mmol/L 0.79 ± 0.26 0.89 ± 0.27 0.31 
Triacylglycerols – mmol/L 1.62 ± 1.43 1.00 ± 0.31 0.11 
Partial pressure of oxygen - kPa 16.4 ± 5.6 18.5 ± 5.5 0.36 
Lactate – mmol/L 0.88 ± 0.33 0.96 ± 0.35 0.58 
Glucose – mmol/L 6.9 ± 2.3 6.1 ± 1.3 0.21 
    
Coronary sinus blood 
3β-hydroxybutyrate – mmol/L 0.15 ± 0.11 0.21 ± 0.16 0.26 
Free fatty acids – mmol/L 0.70 ± 0.33 0.65 ± 0.33 0.68 
Triacylglycerols – mmol/L 1.61 ± 1.44 0.99 ± 0.31 0.11 
Partial pressure of oxygen - kPa 3.4 ± 0.4 3.6 ± 0.5 0.28 
Lactate – mmol/L 0.57 ± 0.27 0.68 ± 0.18 0.21 
Glucose – mmol/L 7.1 ± 2.4 6.1 ± 1.2 0.18 
    
Net myocardial substrates exchange 
β-hydroxybutyrate – mmol/L 0.25 ± 0.18 0.31 ± 0.23 0.52 
Free fatty acids – mmol/L 0.07 ± 0.23 0.25 ± 0.16 0.03 
Triacylglycerols – mmol/L 0.009 ± 0.05 0.007 ± 0.02 0.88 
Partial pressure of oxygen - kPa 12.96 ± 5.56 14.89 ± 5.36 0.39 
Lactate – mmol/L 0.31 ± 0.16 0.26 ± 0.25 0.56 
Glucose – mmol/L -0.12 ± 0.44 -0.17 ± 0.29 0.76 
    
Fractional myocardial substrates extraction 
β-hydroxybutyrate – % 59 ± 35 59 ± 27 0.97 
Free fatty acids – % 4 ± 44 31 ± 19 0.05 
Triacylglycerols – % 1.1 ± 5.3 0.7 ± 2.1 0.83 
Partial pressure of oxygen - % 76 ± 8 78 ± 9 0.66 
Lactate – % 36 ± 13 24 ± 15 0.07 
Glucose – % -2 ± 7 -3 ± 2 0.53 
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Table 5. Variables associated with β-hydroxybutyrate (β-OHB) and fatty acids (FFAs) myocardial 
uptake in patients with heart failure by univariable linear regression model 
 Net myocardial β-OHB extraction 
Net myocardial FFAs 
extraction 
 Regression coefficient p-value 
Regression 
coefficient p-value 
Left ventricular end-diastolic diameter - mm -0.005 0.107 -0.011 <0.001 
Left ventricular end-systolic diameter - mm -0.002 0.328 -0.007 0.001 
Left ventricular ejection fraction - % 0.002 0.395 1.228 0.010 
Heart failure duration - months 0.001 0.050 0.001 0.708 
Left ventricular mass index – gr/m2 -0.001 0.069 -0.002 0.038 
Left atrial volume index - ml/m2 -0.001 0.673 -0.001 0.597 
QRS - msec -0.001 0.163 -0.002 0.094 
TAPSE - mm 0.002 0.818 0.006 0.597 
E/E’ -0.007 0.281 -0.005 0.504 
Right ventricular systolic pressure - mmHg -0.002 0.441 -0.007 0.047 
Inferior vena cava diameter - mm -0.008 0.335 -0.016 0.062 
KCCQ - points 0.002 0.373 0.003 0.223 
Log [BNP]  -0.033 0.284 -0.026 0.489 
Log [Renin]  -1.656 0.202 -1.988 0.050 
Log [Aldosterone]  -1.132 0.067 -1.285 0.022 
Glucose - mmol/L -0.013 0.490 -0.027 0.218 
List of abbreviations: BNP, brain natriuretic peptide; KCCQ, Kansas City Cardiomyopathy Questionnaire; TAPSE, tricuspid 
annular systolic excursion. 
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Figure 1. Heart failure epidemiology A) Hospital discharges for heart failure by sex
(United States: 1980–2010). B) First acute decompensated heart failure annual event
rates per 1000 from ARIC (Atherosclerosis Risk in Communities Study)
Community Surveillance (2005–2013). From: Benjamin EJ, et al. Heart Disease and
Stroke Statistics-2017 Update: A Report From the American Heart Association.
Circulation. 2017 Mar 7;135(10):e146-e603.
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concentration of inhibitory or stimulatory metabolites, or
translocation of metabolic proteins to their site of func-
tion. These mechanisms allow for the rapid adaptation to
acute stresses such as exercise, ischemia, or fasting.
B. Carbohydrate Metabolism
In the well-perfused heart, !60–90% of the acetyl-
CoA comes from !-oxidation of fatty acids, and 10–40%
comes from the oxidation of pyruvate (126, 433, 492,
493, 495) that is derived in approximately equal
amounts from glycolysis and lactate oxidation (126,
433, 492, 493, 495). The glycolytic pathway converts
glucose 6-phosphate and NAD" to pyruvate and NADH
and generates two ATP for each molecule of glucose.
The NADH and pyruvate formed in glycolysis are either
shuttled into the mitochondrial matrix to generate CO2
and NAD" and complete the process of aerobic oxida-
tive glycolysis or converted to lactate and NAD" in the
cytosol (nonoxidative glycolysis).
The healthy nonischemic heart is a net consumer of
lactate even under conditions of near-maximal cardiac
power (204, 292, 426). The myocardium becomes a net
lactate producer only when there is accelerated glycolysis
in the face of impaired oxidation of pyruvate, such as
occurs with ischemia (85, 331, 433) or poorly controlled
diabetes (15, 145, 434). There is a high rate of bidirec-
tional lactate transmembrane flux and conversion to pyru-
vate (125, 141, 204, 293, 492, 493). Lactate transport across
the cardiac sarcolemma is facilitated by the monocar-
boxylic acid transporter-1 (MCT-1) (Fig. 2; Refs. 118, 203).
Glycolytic substrate is derived from exogenous glu-
cose and glycogen stores. Glucose transport into cardio-
myocytes is regulated by the transmembrane glucose gra-
dient and the content of glucose transporters in the sar-
colemma (mainly GLUT-4, and to a lesser extent GLUT-1)
(Fig. 2). There is a translocation of glucose transporters
from intracellular vesicles to the sarcolemmal membrane
in response to insulin stimulation, increased work de-
mand, or ischemia (433, 506, 507), which increases the
membrane capacitance for glucose transport and the rate
of glucose uptake. Translocation of GLUT-4 into the sar-
colemma is also stimulated by activation of AMP-acti-
vated protein kinase (AMPK) (379, 506), which occurs
during exercise stress in the rat heart (71). Mice with
cardiac-specific overexpression of a dominant negative
mutant of AMPK have depressed rates of glucose uptake
(499), suggesting a critical role for AMPK in regulating
basal glucose uptake in the heart. Russell et al. (380)
recently demonstrated that transgenic mice expressing
inactive AMPK have normal GLUT4 expression as well
as baseline and insulin-stimulated cardiac glucose up-
take, but fail to increase glucose uptake and glycolysis
during ischemia (380), illustrating a key role for AMPK
in mediating insulin-independent ischemia-induced glu-
cose uptake.
An additional source of glucose 6-phosphate for the
heart is intracellular glycogen stores. The glycogen pool
in the heart is relatively small (!30 "mol/g wet wt com-
pared with !150 "mol/g wet wt in skeletal muscle) (35,
331, 429) and has a relatively rapid turnover despite stable
tissue concentrations (155). Glycogen concentrations are
increased by an elevated supply of exogenous substrate
and/or hyperinsulinemia (235, 246, 433), and glycogenol-
ysis is activated by adrenergic stimulation (e.g., increases
in cAMP and Ca2"), a fall in the tissue content of ATP, and
a rise in inorganic phosphate such as occur with ischemia
or intense exercise (133, 176, 433). Recently, there has
been considerable interest focused on the role of AMPK in
regulating glycogen content in the heart (9, 71, 499). Con-
stitutively active AMPK due to a mutation in a regulatory
subunit of the enzyme was recently shown to be associ-
FIG. 2. The pathways and regulatory
points of myocardial substrate metabolism.
CPT-I, carnitine palmitoyltransferase-I; FAT,
fatty acid transporter/CD36; G 6-P, glucose
6-phosphate; GLUT, glucose transporters;
MCT, monocarboxylic acid transporters;
PDH, pyruvate dehydrogenase.
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Figure 2. Substrates and related pathways of myocardial energetic metabolism. List
of abbreviations: CPT-I, carnitine palmitoyltransferase-I; FAT, fatty acid
transporter/CD36; G6-P, glucose 6-phosphate; GLUT, glucose transporters; MCT,
monocarboxylic acid transporters; PDH, pyruvate dehydrogenase. From: Stanley
WC, et al. Myocardial substrate metabolism in the normal and failing heart. Physiol
Rev. 2005;85(3):1093-129.
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Figure 3. Metabolic pathways and metabolites that have been shown to be increased
(upward arrows) or reduced (downward arrows) during heart failure. List of
abbreviations: BCAA, branched-chain amino acids. From: Ikegami R, et al.
Metabolomic Analysis in Heart Failure. Circ J 2018; 82: 10–16
Circulation Journal Vol.82, January 2018
13Metabolomic Analysis in HF
in ketone body respiration might enhance mitochondrial 
protein acetylation and suppress mitochondrial activity. 
Despite these potential undesirable effects on the mainte-
nance of energy homeostasis, studies performed in humans 
and rodents indicate a beneficial influence of enhanced 
ketone body metabolism in HF. Thus, further investigation 
is needed to delineate the exact mechanisms involved.
Trimethylamine-N-Oxide
Trimethylamine-N-oxide (TMAO) is generated from 
choline by the gut flora. It is reported that TMAO and 
choline are associated with advanced cardiac dysfunction 
and a worse prognosis in patients with systolic HF inde-
pendent of other cardiac and renal biomarkers.62 The 
circulating TMAO level is elevated in patients with stable 
HF and predicted 5-year mortality.63 In addition, elevation 
of TMAO level is a risk factor for development of HF in 
both diabetic and non-diabetic individuals.64 In a murine 
LV pressure overload model, a diet enriched in TMAO or 
choline was shown to promote cardiac systolic dysfunction, 
together with severe cardiac fibrosis,65 indicating a causative 
role of TMAO in promoting HF pathology. In addition, it 
is reported that TMAO contributes to progression of 
atherosclerotic plaque by reducing reverse cholesterol 
transport.66 TMAO may enhance the pathological activity 
of endothelial cells, macrophages, and platelets, thus 
inducing organ dysfunction in the heart, kidneys, and 
vessels.67 Although further studies are needed to elucidate 
of ketone bodies is increased in the failing hearts of both 
rodents and hum ns.13,56 Levels of β-hydroxybutyrate, a 
ketone body, are increased in the circulation of patients 
with HF, but are reduced in cardiac tissue.13 It is still 
unclear whether increased utilization of ketone bodies is a 
maladaptive or adaptive response. However, results from 
recent clinical trials have suggested that higher circulating 
levels of ketone bodies may suppress progression of HF. It 
is known that ketone body levels are elevated in patients 
taking sodium-glucose cotransporter 2 inhibitors.57 In the 
EMPA-REG outcome study, diabetic patients treated with 
the sodium-glucose cotransporter 2 inhibitor empagliflozin 
showed a 35% relative reduction in the risk of hospitaliza-
tion for HF,58 and elevation of ketone bodies was suggested 
as one of the possible cardioprotective mechanisms. Studies 
have shown that the failing heart can utilize ketone bodies 
effectively, and ketone bodies may ameliorate cardiac 
dysfunction by improving cardiac efficiency.59 According 
to a recent report, cardiac utilization of ketone bodies is 
increased in patients with HF, and interestingly is sup-
pressed in the skeletal muscles of the same individuals. 
Fatty acids, glucose, and ketone bodies are metabolized to 
acetyl-CoA, so increased metabolism of ketone bodies 
could suppress metabolism of the other energy sources and 
promote metabolic dysfunction. In a murine model of LV 
pressure overload, the hypertrophied and failing heart 
shifted to utilization of ketone bodies for ATP production 
at the expense of fatty acid oxidation.56,60,61 An increase 
Figure  1.  Metabolic pathways and metabolites that have been shown to be increased (upward arrows) or reduced (downward 
arrows) in the heart or the circulation (Figure 2) during heart failure. Red metabolites and pathways have been analyzed in humans. 
BCAA, branched-chain amino acids; TCA, tricarboxylic acid.
37
AACS, acetoacetyl-CoA synthetase; a cytoplasmic enzyme
that catalyzes the ATP-dependent covalent activation of ace-
toacetate (AcAc) by CoA to generate AcAc-CoA.
Anaplerosis, essential replenishment of TCA cycle interme-
diates that is required to preserve terminal oxidation of acetyl-
CoA. The primary anaplerotic reaction is catalyzed by pyru-
vate carboxylase, which generates oxaloacetate from pyruvate,
but oxidation of odd-chain fatty acids and amino acid catabo-
lism also yield anaplerotic substrates.
BDH1, mitochondrial !-hydroxybutyrate (!OHB) dehydro-
genase; an enzyme that catalyzes the NAD" /NADH coupled
interconversion of AcAc and D-!OHB. The Keq of this reaction
favors D-!OHB formation.
!-Oxidation, sequential derivation of two carbon units, in
the form of acetyl-CoA, from fatty acyl chains that primarily
occurs within the mitochondrial matrix. Some !-oxidation also
occurs within peroxisomes.
DNL, de novo lipogenesis. The synthesis of new lipid from
acetyl-CoA, dependent on the enzymes acetyl-CoA carboxy-
lase and fatty acid synthase (FAS).
Fluxomics, analysis of metabolic fates of labeled substrates
using sophisticated chemical profiling platforms including,
nuclear magnetic resonance spectroscopy and mass spectrom-
etry, coupled to statistical computing platforms.
Gnotobiotic, Greek roots: gnosis, knowledge; bios, life; a tech-
nology that allows cultivation of experimental animal models in
the presence of defined microbial communities.
GPCR, G protein-coupled receptor; a plasma membrane recep-
tor with seven transmembrane domains that mediates an intracel-
lular signaling cascade via an interaction with a G protein.
HMGCL, HMG-CoA lyase; a mitochondrial enzyme that cleaves
HMG-CoA to liberate AcAc and acetyl-CoA during ketogenesis.
This enzyme mediates ketone body production from !-oxidation-
derived acetyl-CoA and leucine catabolism.
HMGCS2, HMG-CoA synthase 2; a mitochondrial enzyme
that condenses !-oxidation-derived AcAc-CoA and acetyl-
CoA to generate HMG-CoA and liberate a CoA moiety.
Ketogenesis, production of ketone bodies. AcAc and !OHB
are the predominant circulating ketone bodies.
Ketolysis, breakdown of ketone bodies either within the mito-
chondria for terminal oxidation or in the cytoplasm for lipo-
genesis.
Ketone body oxidation, contribution of acetyl-CoA derived
from ketone bodies to the TCA cycle.
Micriobiota, ecosystem of # 100 trillion prokaryotic cells
that comprise a # 1-kg organ that harbors a massive aggregate
of genomes (the microbiome).
NAFLD, nonalcoholic fatty liver disease.
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Fig. 1. Ketone body metabolism pathways. A: ketogenesis within hepatic mitochondria is the primary source of circulating ketone bodies. B: primary metabolic
fate of ketone bodies is terminal oxidation within mitochondria of extrahepatic tissues via CoA transferase [succinyl-CoA:3-oxoacid-CoA transferase (SCOT)].
Substrate competition with pyruvate-derived and fatty acyl-CoA-derived (the corkscrew arrows represent the activities of the !-oxidation spiral) acetyl-CoA are
shown. C: cytoplasmic de novo lipogenesis (DNL) and cholesterol synthesis are nonoxidative metabolic fates of ketone bodies. For simplicity of C, only
acetoacetate (AcAc) is depicted, although !-hydroxybutyrate (!OHB) is also a substrate for lipogenesis after it has been oxidized to AcAc via mitochondrial
!OHB dehydrogenase (BDH1). AACS, acetoacetyl-CoA synthetase; ACC, acetyl-CoA carboxylase; AcAc-CoA, acetoacetyl-CoA; ATP, adenosine triphosphate;
CoA-SH, free coenzyme A; FAS, fatty acid synthase; HMG-CoA, 3-hydroxymethylglutaryl-CoA; HMGCL, HMG-CoA lyase; HMGCS1, cytoplasmic
HMG-CoA synthase; HMGCS2, mitochondrial HMG-CoA synthase; HMGCR, HMG-CoA reductase; NAD" (H), nicotinamide adenine dinucleotide oxidized
(reduced); PDH, pyruvate dehydrogenase; TCA, tricarboxylic acid; mThiolase, mitochondrial thiolase; cThiolase, cytoplasmic thiolase. Thiolase activity is
encoded by at least 6 genes: ACAA1, ACAA2 (encoding an enzyme known as T1 or CT), ACAT1 (encoding T2), ACAT2, HADHA, and HADHB.
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Figure 4. Ketone body metabolism pathways. Terminal oxidation of ketone bodies
within mitochondria of extrahepatic tissues via CoA transferase [succinyl-CoA:3-
oxoacid-CoA transferase (SCOT)]. Substrate competition with pyruvate-derived and
fatty acyl-CoA-derived (the corkscrew arrows represent the activities of the ß-
oxidation spiral) acetyl-CoA are shown. List of abbreviations: AcAc, acetoacetate;
AcAc-CoA, acetoacetyl-CoA; ATP, adenosine triphosphate; ßOHB, ß-
hydroxybutyrate; CoA-SH, free coenz me A; NAD+(H), nicotinamide adenin
dinucleotide oxidized (reduced); PD , pyruvate dehydrogenase; TCA, tricarboxylic
acid; mThiolase, mitochondrial thiolase. From: Cotter DG, et al. Ketone body
metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol.
2013;304(8):H1060-76.
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failing heart. Because ketone availability is a primary deter-
minant of ketone utilization, these observations suggest that 
impaired systemic metabolism is an important contributor to 
remodeling of cardiac metabolism in advanced HF.
Data obtained from mouse hearts provided a different per-
spective to this question, however. Aubert et al5 observed a 
consistent upregulation of BDH1 in mouse hearts with patho-
logical hypertrophy and failure despite similar circulating 
ketone levels, suggesting that an increased BDH1 level could 
accelerate ketone metabolism during the development of HF. 
Using stable isotope labeling techniques in isolated perfused 
hearts, the group showed a significant increase in the relative 
oxidation of βOHB in hypertrophied mouse hearts that coin-
cided with the upregulation of BDH1. Because the concen-
tration of βOHB (1 mmol/L) used in perfusion experiments 
was several-fold higher than serum levels in mice or humans 
with HF, future studies are warranted to determine whether the 
upregulation of BDH1 increases the use of ketone supplied at 
an in vivo concentration. Nevertheless, the efforts of Aubert 
et al5 and Bedi et al6 have identified a novel aspect of cardiac 
metabolism in the failing heart that has high clinical relevance 
and opens up new opportunities for translational research in 
metabolic therapy for HF.
Despite unambiguous observations, the mechanism for 
increased myocardial ketone oxidation remains unclear. Both 
studies showed evidence of impaired fatty acid oxidation 
(FAO) in the failing heart, suggesting that increased ketone 
use could be a part of the metabolic remodeling that shifts the 
substrate utilization toward non–fatty acid sources. The mouse 
study found marked downregulation of proteins involved in 
FAO, implying a decrease in the capacity of FAO in the failing 
heart. This is consistent with prior studies demonstrating accu-
mulation of intermediate metabolites of fatty acid metabolism 
in the heart of animal models of HF and patients with HF.7,8 
The human study, however, found a depletion rather than an 
accumulation of myocardial lipid intermediates, particularly 
long-chain acylcarnitines. In contrast to the proteomics data 
from mice, gene expression for proteins involved in fatty acid 
β-oxidation or peroxisome proliferator-activated receptor-α 
was unchanged, whereas transporters for carnitine were 
downregulated in cardiac tissue of patients with advanced HF. 
Thus, FAO is decreased in the failing mouse heart because the 
system is “jammed,” whereas in the human failing heart, the 
system is “deprived.” Although increased ketone utilization is 
coupled with decreased FAO, the underlying mechanisms for 
impaired FAO in the failing hearts of mice and human could 
be distinct. This does not, however, rule out the possibility that 
observations made in the cardiac tissue obtained from patients 
with advanced HF are unique to the end-stage disease, which 
is not comparable to the stable HF stage represented by the 
mouse model. Future studies are necessary to clarify this point 
and, more important, to determine whether impaired FAO is 
the cause of increased reliance on ketone as an energy source 
in HF. Furthermore, the present studies focused on nondia-
betic, nonobese HF models/patients, which allows demonstra-
tion of a diabetes mellitus–independent increase in cardiac 
ketone utilization in HF. Because diabetes mellitus is present 
in ≈40% of patients hospitalized with HF,9 it will be important 
to consider the influence of comorbidities on ketone metabo-
lism in future experimental models.
An important question raised by the studies is whether 
the increased reliance on ketone body metabolism is adap-
tive or maladaptive for the failing heart. Deletion of SCOT 
in mouse hearts promotes pathological remodeling and car-
diac dysfunction after transverse aortic constriction,10 sug-
gesting that the ability to oxidize ketone bodies is important 
for the failing heart. An elevation in serum ketone levels has 
now been observed by several studies in patients with HF.6,11,12 
Therefore, the present data suggest that the increase in myo-
cardial ketone body utilization is a consequence of increased 
systemic availability. In end-stage HF, insulin resistance and 
cardiac cachexia are common, which increases the likelihood 
of ketone production by the liver and renders cardiac ketone 
utilization unavoidable. Because the metabolite profile associ-
ated with increased ketone oxidation is indicative of impaired 
TCA cycle fluxes in the failing hearts,6 measures to reduce the 
reliance on ketone bodies are likely desirable. In this regard, 
preventing the decrease in myocardial FAO during the devel-
opment of pathological hypertrophy is worth consideration.13 
In turn, measures to tailor nutritional interventions or to opti-
mize systemic metabolism to attenuate hepatic ketone body 
production may also be a potential therapeutic approach.
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Figure. Ketone metabolism is increased in failing hearts 
of mice and humans. The major findings of altered 
ketone body (red) and fatty acid (blue) metabolism 
from the present studies in failing mice and humans 
are summarized. Decreased fatty acid oxidation was 
evidenced by a reduction in long-chain acylcarnitines 
and reduced protein abundance of several enzymes 
in β-oxidation (β-ox). Elevations in serum ketone 
body concentration were matched by alterations in 
metabolites and enzymes that are consistent with the 
upregulation of the ketone oxidation pathway. Green 
arrows show findings in mouse heart failure (HF); yellow 
arrow, findings in human HF. Acac CoA indicates aceto-
acetyl CoA; BDH1, mitochondrial β-hydroxybutyrate 
dehydrogenase; βOHB, β-hydroxybutyrate; βOHB 
CoA, β-hydroxybutyryl CoA; C2-carnitine, acetyl-
carnitine; C4-OH carnitine, hydroxybutyrylcarnitine; 
and SCOT, succinyl-CoA:3-oxoacid-CoA transferase.
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Figure 5. Ketone metabolism in failing heart. Green arrows show findings in mouse
heart failure (HF); yellow arrow, find ngs in human HF. Acac CoA indicates aceto-
acetyl CoA; BDH1, mitochondrial β-hydroxybutyrate dehydrogenase; βOHB, β-
hydroxybutyrate; βOHB CoA, β-hydroxybutyryl CoA; C2-carnitine, acetyl-
carnitine; C4-OH carnitine, hydroxybutyrylcarnitine; and SCOT, succinyl-CoA:3-
oxoacid-CoA transferase. From: Kolwicz SC Jr, et al. Ketones Step to the Plate: A
Game Changer for Metabolic Remodeling in Heart Failure? Circulation. 2016 Feb
23;133(8):689-91.
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failing heart. Because ketone availability is a primary deter-
minant of ketone utilization, these observations suggest that 
impaired systemic metabolism is an important contributor to 
remodeling of cardiac metabolism in advanced HF.
Data obtained from mouse hearts provided a different per-
spective to this question, however. Aubert et al5 observed a 
consistent upregulation of BDH1 in mouse hearts with patho-
logical hypertrophy and failure despite similar circulating 
ketone levels, suggesting that an increased BDH1 level could 
accelerate ketone metabolism during the development of HF. 
Using stable isotope labeling techniques in isolated perfused 
hearts, the group showed a significant increase in the relative 
oxidation of βOHB in hypertrophied mouse hearts that coin-
cided with the upregulation of BDH1. Because the concen-
tration of βOHB (1 mmol/L) used in perfusion experiments 
was several-fold higher than serum levels in mice or humans 
with HF, future studies are warranted to determine whether the 
upregulation of BDH1 increases the use of ketone supplied at 
an in vivo concentration. Nevertheless, the efforts of Aubert 
et al5 and Bedi et al6 have identified a novel aspect of cardiac 
metabolism in the failing heart that has high clinical relevance 
and opens up new opportunities for translational research in 
metabolic therapy for HF.
Despite unambiguous observations, the mechanism for 
increased myocardial ketone oxidation remains unclear. Both 
studies showed evidence of impaired fatty acid oxidation 
(FAO) in the failing heart, suggesting that increased ketone 
use could be a part of the metabolic remodeling that shifts the 
substrate utilization toward non–fatty acid sources. The mouse 
study found marked downregulation of proteins involved in 
FAO, implying a decrease in the capacity of FAO in the failing 
heart. This is consistent with prior studies demonstrating accu-
mulation of intermediate metabolites of fatty acid metabolism 
in the heart of animal models of HF and patients with HF.7,8 
The human study, however, found a depletion rather than an 
accumulation of myocardial lipid intermediates, particularly 
long-chain acylcarnitines. In contrast to the proteomics data 
from mice, gene expression for proteins involved in fatty acid 
β-oxidation or peroxisome proliferator-activated receptor-α 
was unchanged, whereas transporters for carnitine were 
downregulated in cardiac tissue of patients with advanced HF. 
Thus, FAO is decreased in the failing mouse heart because the 
system is “jammed,” whereas in the human failing heart, the 
system is “deprived.” Although increased ketone utilization is 
coupled with decreased FAO, the underlying mechanisms for 
impaired FAO in the failing hearts of mice and human could 
be distinct. This does not, however, rule out the possibility that 
observations made in the cardiac tissue obtained from patients 
with advanced HF are unique to the end-stage disease, which 
is not comparable to the stable HF stage represented by the 
mouse model. Future studies are necessary to clarify this point 
and, more important, to determine whether impaired FAO is 
the cause of increased reliance on ketone as an energy source 
in HF. Furthermore, the present studies focused on nondia-
betic, nonobese HF odels/patients, which allows demonstra-
tion of a diabetes mellitus–independent increase in cardiac 
ketone utilization in HF. Because diabetes mellitus is present 
in ≈40% of patients hospitalized with HF,9 it will be important 
to consider the influence of comorbidities on ketone metabo-
lism in future experimental models.
An important question raised by the studies is whether 
the increased reliance on ketone body metabolism is adap-
tive or maladaptive for the failing heart. Deletion of SCOT 
in mouse hearts promotes pathological remodeling and car-
diac dysfunction after transverse aortic constriction,10 sug-
gesting that the ability to oxidize ketone bodies is important 
for the failing heart. An elevation in serum ketone levels has 
now been observed by several studies in patients with HF.6,11,12 
Therefore, the present data suggest that the increase in myo-
cardial ketone body utilization is a consequence of increased 
systemic availability. In end-stage HF, insulin resistance and 
cardiac cachexia are common, which increases the likelihood 
of ketone production by the liver and renders cardiac ketone 
utilization unavoidable. Because the metabolite profile associ-
ated with increased ketone oxidation is indicative of impaired 
TCA cycle fluxes in the failing hearts,6 measures to reduce the 
reliance on ketone bodies are likely desirable. In this regard, 
preventing the decrease in myocardial FAO during the devel-
opment of pathological hypertrophy is worth consideration.13 
In turn, measures to tailor nutritional interventions or to opti-
mize systemic metabolism to attenuate hepatic ketone body 
production may also be a potential therapeutic approach.
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Figure 6. Substrates concentrations in (A) arterial and (B) coronary sinus samples
(mean ± SD).
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Figure 7. Heart metabolism in heart failure patients and controls. A) net myocardial
substrates exchange (axillary artery – coronary sinus) and B) fractional myocardial
substrates extraction. Lines and brackets represent mean ± SD.
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Figure 8. Heart metabolism in heart failure patients with and without diabetes (DM).
A) net myocardial substrates exchange (axillary artery – coronary sinus) and B)
fractional myocardial substrates extraction. Lines and brackets represent mean ±
SD.
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Figure 9. Association between net myocardial free fatty acids (FFAs) exchange and
A) left ventricular end-diastolic diameter; B) left ventricular ejection fraction; C) left
ventricular mass.
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Figure 10. Association net myocardial free fatty acids (FFAs) exchange and
neurohormones: A) aldosterone; B) renin.
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Figure 11. Large figure: association between net myocardial β-hydroxybutyrate
(3B-OHB) exchange and heart failure (HF) duration. Small figure: association
between β-hydroxybutyrate plasma concentration and HF duration
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Figure 12. Association between plasma concentrations of β-hydroxybutyrate (3B-
OHB) and triacilgliceroles in A) heart failure and B) non-heart failure patients.
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